Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.
|
31714276 |
2020 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we present the case of a 49-year-old man with pancreatoblastoma and liver metastasis who underwent preoperative multimodal imaging, in which F-FDG PET/CT showed a markedly increased F-FDG uptake in the metastatic lesion and a slightly increased uptake in the primary lesion.
|
31274558 |
2020 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.
|
31612350 |
2020 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of [<sup>18</sup>F]FDG/[<sup>18</sup>F]FLT/[<sup>18</sup>F]FMISO-based micro-positron emission tomography in detection of liver metastasis in human colorectal cancer.
|
31330410 |
2020 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the feasibility of US-<sup>18</sup>FDG-PET/CT fusion-guided microwave ablation of liver metastases either poorly visible or totally undetectable with US, CEUS and CT, but visualized by PET imaging.
|
30288593 |
2019 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Staging with F-FDG PET/CT demonstrated lymph node and liver metastasis.
|
30371587 |
2019 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer.
|
31267161 |
2019 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the feasibility of early metabolic response assessment with <sup>18</sup>F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres.
|
31167272 |
2019 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features.
|
30927933 |
2019 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of <sup>18</sup>F-FDG PET/CT in patients with colorectal cancer liver metastases after hepatectomy.
|
29459018 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
TLG response assessment on <sup>18</sup>F-FDG PET/CT appears to be more sensitive and accurate, especially at early follow-up, than size-based response assessment on MR imaging in patients with CRLM treated by RE.
|
29249594 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine whether intraprocedural <sup>18</sup>F-FDG PET/CT can be used as a predictor of local tumor progression after percutaneous ablation of colorectal liver metastases.
|
29439012 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Artifactual Hepatic Metastasis on FDG PET/CT Secondary to Cryoablation for Adrenal Metastasis.
|
29232243 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
A staging FDG PET/CT was performed for a 43-year-old woman who was suspected to have splenic malignancy with multiple hepatic metastases revealed on CT images.
|
29356748 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The <sup>18</sup>F-FDG PET/CT detected more pulmonary nodules in four patients (one PMCRC in each of these patients) and more extrapulmonary disease in six patients (four mediastinal lymph nodes, one retroperitoneal lymph node and one liver metastases) that the CT-scan had not detected.
|
29034693 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
An F-FDG PET/CT was performed on a 74-year-old woman with pancreatic carcinoma and liver metastases.
|
30300198 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognostic value of <sup>18</sup>F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases.
|
29026950 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ADCcv index is a potential biomarker of LM with better correlation to <sup>18</sup>F-FDG PET SUVpeak than conventional MRI metrics, and may serve to quantitatively discriminate between LM and NAL.
|
29859634 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor-to-background ratio of the liver metastases was significantly higher in patients where F-FDG PET/CT detected extrahepatic disease (P=0.03).
|
29683930 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, F-FDG PET/CT showed the presence of 146 liver metastases in 57 patients.
|
30216230 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Imaging with F-FDG PET showed low glucose avidity in disease sites but Ga-PSMA PET unequivocally demonstrated multiple skeletal and liver metastases with intense PSMA avidity.
|
30036256 |
2018 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patient underwent FDG PET/CT for staging, which demonstrated the hypermetabolic pancreatic mass with multiple liver metastases.
|
28098663 |
2017 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases.
|
28180965 |
2017 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apart from showing increased FDG uptake in the primary site and locoregional nodal and liver metastases, an unusual site of intense FDG focus was demonstrated in the left adrenal gland.
|
28632691 |
2017 |
Secondary malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diffuse bone and liver metastases were gallium-DOTATOC PET-positive with only mild uptake on FDG PET/CT.
|
29145267 |
2017 |